ClinicalTrials.gg
Not yet recruitingNCT07859163Updated Oct 5, 2026

Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain

A Phase 4 interventional study of Semaglutide weekly injection and Placebo in Morbid Obesity, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.

Planned enrollment
25th of 69
100 · median 90
Started
2026
with 9 others
Phase 4
6 of 76
5 open now
Primary completion
2029-04
later than 14 of 15 live
Registered
69th of 76
by date
Lead sponsor
8 of 76
General Committee of Teaching Hospitals and Institutes, Egypt

Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is the 25th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 14 of the 15 other live ones, and was the 69th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Obesity, Morbid with a site in Egypt, or all of them as a file.
02

Study summary

Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented. A 2026 international Delphi consensus has now standardized the definition. This trial uses that definition. So does our companion trial, RESURGE.

We have two real treatments. Both work. Neither is enough. Conversion of SG to RYGB gives around 20% additional total weight loss at 12 months across all indications, and less when the indication is poor weight response rather than reflux. Drug therapy also works after MBS. Liraglutide beat placebo by about 8 percentage points in the BARI-OPTIMISE randomized trial. Semaglutide gives around 11% total weight loss and tirzepatide around 14% in pooled retrospective data, including specifically after SG. Most patients do not return to their nadir weight with either option alone.

The field is already comparing the two strategies, but only retrospectively. Two 2025 multicenter cohorts compared conversion against GLP-1 therapy after SG. These studies cannot control diet, exercise, supplementation, co-medication, or adherence. They cannot settle the question.

The societies agree on the pathway but admit the evidence is weak. The 2024 IFSO position statement and the 2026 ASMBS statement say the same thing: work up the anatomy first; operate when there is a structural problem; consider medical therapy when there is not; and consider combining drug therapy with revision. The 2024 IFSO international consensus goes further: with 92% agreement, it states that medications should generally be considered before revisional surgery for recurrent weight gain. Every one of those recommendations rests on consensus and retrospective data. None rests on a randomized trial. This protocol is that trial.

Read the detailed description

The biology says the combination should win. Revision restores restriction and corrects anatomy. It does not correct appetite biology. Patients with poor response after MBS show blunted satiety-hormone profiles, which is exactly what GLP-1 therapy replaces. The operation and the drug cover each other's weakness. They are complementary tools, not competitors.

Medical therapy alone has a durability problem. When the drug stops, weight returns. SURMOUNT-4 showed rapid regain after tirzepatide withdrawal, and meta-analysis confirms the pattern across agents. Surgery provides the durable base. The drug adds effect where it is needed most: around the revision. That is the logic of the sandwich.

The pre-operative phase has three jobs. It tests whether the patient tolerates and responds to the drug before we commit to a reoperation. It produces weight loss before revisional surgery, where technical difficulty and risk are higher than in primary surgery. And it gives strong medical responders a genuine chance to avoid the reoperation altogether.

Some patients on active drug will lose enough weight before surgery to step off the operating list. We expect this. It is not a flaw and it is not contamination. It is a pre-specified secondary endpoint. It is also the first randomized test of the advice the guidelines already give: try medical therapy first when the anatomy is normal. Patients whose anatomy forces surgery are not in this trial at all; they go straight to the operating room, as they should.

Every published combination series is confounded. Diet, exercise, supplements, other drugs, and adherence differ between patients and are rarely measured. This protocol standardizes all of them in both arms and measures them objectively. Section 8 lists each confounder and what we do about it.

03

Conditions studied

  • Morbid Obesity

Keywords

  • SANDWICH
  • Semaglutide
  • conversion of sleeve gastrectomy to Roux-en-Y gastric bypass
  • sleeve gastrectomy
  • Roux-en-Y gastric bypass
  • recurrent weight gain
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SG at least 2 years before screening.
  • Recurrent weight gain meeting the international Delphi consensus definition. Operational entry threshold for this trial: regain of at least 20% of the maximal weight lost, measured from nadir.
  • of 35 kg/m² or more, or 30 kg/m² or more with at least one obesity-associated disease, and accepted for conversion to RYGB by the multidisciplinary team.
  • Upper endoscopy and contrast imaging completed.
  • Able to give written .

Exclusion criteria

Exclusion Criteria:

  • Anatomy. These patients need surgery regardless of drug response, so randomizing them is not ethical. They are operated outside the trial. This is the operational form of the rule: anatomical cause, direct surgery; no anatomical cause, eligible for the trial.

    • Staple-line leak or gastric fistula.
    • Sleeve stenosis or axial twist.
    • Hiatal hernia larger than 3 cm.
    • Los Angeles grade C or D esophagitis, or Barrett's esophagus.
  • Drug and general safety

    • GLP-1 receptor agonist use within the last 6 months, or previous intolerance.
    • History of pancreatitis.
    • Personal or family history of medullary thyroid carcinoma or MEN2.
    • Type 1 diabetes; below 30 mL/min/1.73 m²; active .
    • Pregnancy, breastfeeding, or pregnancy plans during the study. Women of must use reliable . Per current labeling and the 2026 Standards, obesity pharmacotherapy is stopped at least 2 months before any planned conception.
    • Uncontrolled psychiatric disease or active substance use disorder.
    • Current smoking, unless cessation is completed before surgery per unit policy.
    • Any other anti-obesity medication within the last 3 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    GLP 1

    Semaglutide 2.4 mg weekly: 16 weeks before conversion, held 7 days before surgery, restarted 4 weeks after surgery, continued to 12 months after surgery.

    Drug: Semaglutide weekly injection

  • Placebo comparator
    Placebo

    Matched placebo on the identical schedule.

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Weekly subcutaneous injections from identical, pharmacy-labelled pens. The active arm receives semaglutide 2.4 mg. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm.

  • DrugPlacebo

    Weekly subcutaneous injections from identical, pharmacy-labelled pens. The placebo arm receives matched placebo. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm.

06

What researchers measure

Primary outcomes

  1. Percentage total weight loss

    Measured in kilograms at month 18 after randomization. Baseline is the randomization weight.

    Time frame: Baseline till 30 months

Secondary outcomes

  1. BMI change

    Equation: BMI = weight (In kilograms) / \[height (In meters)\]\^2

    Time frame: 0, 3, 6, 9, 12 months

  2. change in HbA1c

    An HbA1c level reflects your average blood sugar over the past two to three months, and any meaningful change typically takes at least 6 weeks to show because red blood cells live for about 3 months. Normal: Below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or higher

    Time frame: 0, 6, 12 months

  3. systolic and diastolic blood pressure

    Normal blood pressure is less than 120 mm Hg systolic and less than 80 mm Hg diastolic. Systolic (Top Number): Measures the pressure in your arteries when your heart beats and contracts. Diastolic (Bottom Number): Measures the pressure in your arteries when your heart rests between beats. Normal: Less than 120 mm Hg systolic and less than 80 mm Hg diastolic. Elevated: 120-129 mm Hg systolic and less than 80 mm Hg diastolic. Stage 1 Hypertension (High Blood Pressure): 130-139 mm Hg systolic or 80-89 mm Hg diastolic. Stage 2 Hypertension: 140 mm Hg or higher systolic, or 90 mm Hg or higher diastolic. Hypertensive Crisis: Higher than 180 mm Hg systolic and/or higher than 120 mm Hg diastolic. This requires immediate emergency medical care

    Time frame: 0, 6, 12 months

  4. total cholesterol, LDL, HDL, and triglycerides

    Normal adult values for a lipid panel are measured in milligrams per deciliter (mg/dL): Total Cholesterol: Below 200 mg/dL is desirable. (Borderline high is 200-239 mg/dL, and high is 240 mg/dL and above.) LDL ("Bad") Cholesterol: Below 100 mg/dL is optimal. (130-159 mg/dL is borderline high, and 160-189 mg/dL or higher is high.) HDL ("Good") Cholesterol: 60 mg/dL and higher is protective. Levels below 40 mg/dL for men or below 50 mg/dL for women are considered low. Triglycerides: Below 150 mg/dL is normal. (Borderline high is 150-199 mg/dL, and high is 200-499 mg/dL.)

    Time frame: 0, 6, 12 months

  5. Operative time

    From the start till the end of the surgery measured in minutes

    Time frame: At the time or during surgery

  6. Intraoperative adverse events

    Adverse intraoperative events (AIEs) occur in approximately 3% to 7% of bariatric surgeries and increase the relative risk of overall postoperative complications by about 90%. Organ Injuries: Unintentional lacerations or punctures to the liver, spleen, stomach, intestines, or major blood vessels during trocar placement or dissection. Intraoperative Bleeding: Significant hemorrhage from staple lines, mesentery, or the abdominal wall requiring intervention or transfusion. Anastomosis and Staple Line Issues: Leaks, bleeding, or technical difficulties during the creation of pouches or connections (such as in a Roux-en-Y Gastric Bypass), identified via intraoperative leak tests. Equipment Malfunction: Failures involving laparoscopic staplers, cameras, insufflation systems, or energy devices. Anesthesia-Related Events: Severe hemodynamic instability, difficult airway management, or allergic reactions linked to medications.

    Time frame: At the time or during surgery

  7. 30-day complications

    The Clavien-Dindo Classification grades 30-day postoperative complications based on the level of medical or surgical therapy needed to treat them. Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Grade II: Requiring pharmacological treatment with drugs other than those allowed for Grade I, including blood transfusions and total parenteral nutrition. Grade III: Requiring surgical, endoscopic, or radiological intervention. Grade IIIa: Intervention not under general anesthesia. Grade IIIb: Intervention under general anesthesia. Grade IV: Life-threatening complication (including central nervous system complications) requiring intermediate care or intensive care unit (ICU) management. Grade V: Death of a patient.

    Time frame: postoperative till 30 days

  8. change in GerdQ score

    A change in the GerdQ score reflects how gastroesophageal reflux disease (GERD) symptoms and their daily impact respond to treatment or evolve over time. Range: The total score spans from 0 to 18. Diagnosis Threshold: A score of 8 or higher indicates a high likelihood of GERD. Components: It evaluates four positive predictors (heartburn, regurgitation, sleep disturbance, and over-the-counter medication use) and two negative predictors (epigastric pain and nausea) over the past 7 days. Decrease in Score: A lowering score (especially moving from ≥ 8 to \< 8) typically indicates successful treatment response, reduced symptom frequency, and lower disease impact. Increase or No Change: A rising score or a score that remains persistently above 8 suggests ongoing treatment failure, unmanaged symptom triggers, or disease progression.

    Time frame: 0, 6, 12 months

  9. change in IWQOL-Lite-CT total and domain scores

    The IWQOL-Lite-CT (Impact of Weight on Quality of Life-Lite Clinical Trials Version) score ranges from 0 to 100, where 100 represents the best possible quality of life and functioning (meaning zero weight-related impairment). Total Score Range: 0-100 (higher = better quality of life) Domain/Composite Scores: 0-100 Raw scores are converted or transformed to a 0-100 scale for standard reporting.

    Time frame: 0, 6, 12 months

  10. change in fat mass and lean soft tissue mass

    (bioelectrical impedance analysis, standardized hydration instructions), with fat-free mass loss reported as a proportion of total weight change and hand-grip strength measured at weeks 0, 32, and 68, so that mass is interpreted together with function per the ESPEN/EASO sarcopenic-obesity framework and current meta-analytic evidence.

    Time frame: 0, 6, 12 months

  11. Hand-grip strength

    A hand grip strength test measures the maximum force of your hand and forearm muscles using a portable device called a handgrip dynamometer. Position yourself: Sit up straight with your feet flat on the floor. Place your arm by your side with your elbow bent at a 90-degree angle and your wrist in a neutral position. Hold the device: Adjust the handle so it fits comfortably in your hand. Squeeze hard: Squeeze the handles as hard as you can for about 3 to 5 seconds without moving your arm or resting the device against your body. Repeat trials: Take three measurements for each hand, resting for 15 to 30 seconds between attempts. Use either the highest score or the average of the trials. A normal hand grip strength score typically ranges from 40 to 56 kg (88 to 123 lbs) for adult men and 25 to 36 kg (55 to 79 lbs) for adult women aged 20-29.

    Time frame: 0, 6, 12 months

  12. Safety of the drug phase

    all adverse events, with events of special interest: pancreatitis, gallstones, severe gastrointestinal intolerance, hypoglycemia, dumping, aspiration at induction, venous thromboembolism, mortality.

    Time frame: Baseline till 30 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859163
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Responsible party
Mohamed Hany Ashour (Professor, Surgeon, General Committee of Teaching Hospitals and Institutes, Egypt) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Mohamed Hany Ashour, Professor, MD
Contact
mohamed.ashour@alexu.edu.eg
+201002600970

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion